Efficacy of antithrombin in preclinical and clinical applications for sepsis-associated disseminated intravascular coagulation

Journal of Intensive Care

Volumn 2, Issue 1, 2014, Pages

  Iba, Toshiaki ^a   Saitoh, Daizoh ^b  

^a JUNTENDO UNIVERSITY   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Antithrombin; Damage associated molecular pattern; Disseminated intravascular coagulation; Heparin; Necrosis; Neutrophil extracellular traps; Protease activated receptor; Sepsis; Syndecan 4; Thrombin

Indexed keywords

ANTITHROMBIN; CYTOKINE; HEPARIN; PROSTACYCLIN; PROTEIN C; PROTEINASE ACTIVATED RECEPTOR 1; SYNDECAN 4; THROMBIN;

ARTICLE; BLEEDING; CELL DEATH; CONFORMATIONAL TRANSITION; CONTROLLED CLINICAL TRIAL (TOPIC); DISSEMINATED INTRAVASCULAR CLOTTING; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; EXTRACELLULAR TRAP; HUMAN; MORBIDITY; MORTALITY; MULTICENTER STUDY (TOPIC); NECROSIS; NEUTROPHIL; NONHUMAN; ORGAN DYSFUNCTION SCORE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; SEPSIS; SURVIVAL;

EID: 84979198277     PISSN: None     EISSN: 20520492     Source Type: Journal    
DOI: 10.1186/s40560-014-0051-6     Document Type: Article

References (63)

1. Hunt BJ. Bleeding and coagulopathies in critical care. N Engl J Med 2014, 370:847-859. 10.1056/NEJMra1208626, 24571757.
2. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med 2010, 38(Suppl):S26-S34. 10.1097/CCM.0b013e3181c98d21, 20083910.
3. Iba T, Gando S, Thachil J. Anticoagulant therapy for sepsis-associated disseminated intravascular coagulation: the view from Japan. J Thromb Haemost 2014, 12:1010-1019. 10.1111/jth.12596, 24801203.
4. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gårdlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR, Thompson V, Janes J, Macias WL, Vangerow B, Williams MD. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012, 366:2055-2064. 10.1056/NEJMoa1202290, 22616830.
5. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Pénzes I, Kübler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001, 286:1869-1878. 10.1001/jama.286.15.1869, 11597289.
6. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Peckelsen C, De Deyne C, Postier R, Pettilä V, Artigas A, Percell SR, Shu V, Zwingelstein C, Tobias J, Poole L, Stolzenbach JC, Creasey AA. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. J Am Med Assoc 2003, 290:238-247. 10.1001/jama.290.2.238.
7. Dhainaut JF, Yan SB, Joyce DE, Pettilä V, Basson B, Brandt JT, Sundin DP, Levi M. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Tromb Haemost 2004, 2:1924-1933. 10.1111/j.1538-7836.2004.00955.x.
8. Kienast J, Juers M, Wiedermann CJ, Hoffmann JN, Ostermann H, Strauss R, Keinecke HO, Warren BL, Opal SM. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Tromb Haemost 2006, 4:90-97. 10.1111/j.1538-7836.2005.01697.x.
9. Gando S, Saitoh D, Ishikura H, Ueyama M, Otomo Y, Oda S, Kushimoto S, Tanjoh K, Mayumi T, Ikeda T, Iba T, Eguchi Y, Okamoto K, Ogura H, Koseki K, Sakamoto Y, Takayama Y, Shirai K, Takasu O, Inoue Y, Mashiko K, Tsubota T, Endo S: A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Crit Care 2013, 17:R297.
10. Wada H, Thachil J, Di Nisio M, Mathew P, Kurosawa S, Gando S, Kim HK, Nielsen JD, Dempfle CE, Levi M, Toh CH. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost 2013, 11:761-767. 10.1111/jth.12155.
11. Iba T, Kidokoro A. High-dose antithrombin therapy for sepsis: mechanisms of action. Shock 2002, 18:389-394. 10.1097/00024382-200211000-00001, 12412615.
12. Hoffmann JN, Muhlbayer D, Jochum M, Inthorn D. Effect of long-term and high-dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Crit Care Med 2004, 32:1851-1859. 10.1097/01.CCM.0000139691.54108.1F, 15343012.
13. Moulin F, Pearson JM, Schultze AE. Thrombin is a distal mediator of lipopolysaccharide-induced liver injury in the rat. J Surg Res 1996, 65:149-158. 10.1006/jsre.1996.0358, 8903462.
14. Moser R, Groscurth P, Fehr J. Promotion of transendothelial neutrophil passage by human thrombin. J Cell Sci 1990, 96:737-744. 2283362.
15. Shankar R, de la Motte CA, Poptic EJ, DiCorleto PE. Thrombin receptor activating peptides differentially stimulate platelet derived growth factor production, monocytic cell adhesion, and E-selectin expression in human umbilical vein endothelial cells. J Biol Chem 1994, 269:13936-13941. 7514596.
16. Sugama Y, Tiruppathi C, Offakidevi K, Andersen TT, Fenton JW, Malik AB. Thrombin-induced expression of endothelial P-selectin and intracellular adhesion molecule-1: a mechanism for stabilizing neutrophil adhesion. J Cell Biol 1992, 119:935-944. 10.1083/jcb.119.4.935, 1385447.
17. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000, 407:258-264. 10.1038/35025229, 11001069.
18. Ossovskaya VS, Bunnett NW. Protease-activated receptors: contribution to physiology and disease. Physiol Rev 2004, 84:579-621. 10.1152/physrev.00028.2003, 15044683.
19. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002, 296:1880-1882. 10.1126/science.1071699, 12052963.
20. Roemisch J, Gray E, Hoffmann JN, Wiedermann CJ. Antithrombin: a new look at the actions of a serine protease inhibitor. Blood Coagul Fibrinol 2002, 13:657-670. 10.1097/00001721-200212000-00001.
21. Uchiba M, Okajima K. Antithrombin III (AT III) prevents LPS-induced pulmonary vascular injury: novel biological activity of AT III. Semin Thromb Hemost 1997, 23:583-590. 10.1055/s-2007-996140, 9469634.
22. Koca U, Olguner C, Ozkardeşler S, Karci A, Coker C, Tuncel P, Taşdöĝen A, Duru S, Ulukuş C, Elar Z. Antithrombin III pretreatment reduces neutrophil recruitment into the lung in a rat model of abdominal sepsis. Acta Anaesthesiol Scand 2005, 49:203-208. 10.1111/j.1399-6576.2004.00567.x, 15715622.
23. Zhou W, Hashimoto K, Goleniewska K, O'Neal JF, Ji S, Blackwell TS, Fitzgerald GA, Egan KM, Geraci MW, Peebles RS. Prostaglandin I2 analogs inhibit proinflammatory cytokine production and T cell stimulatory function of dendritic cells. J Immunol 2007, 178:702-710. 10.4049/jimmunol.178.2.702, 17202330.
24. Nishijima K, Kiryu J, Tsujikawa A, Honjo M, Nonaka A, Yamashiro K, Kamizuru H, Ieki Y, Tanihara H, Honda Y, Ogura Y. Inhibitory effects of antithrombin III on interactions between blood cells and endothelial cells during retinal ischemia-reperfusion injury. Invest Ophthalmol Vis Sci 2003, 44:332-341. 10.1167/iovs.02-0493, 12506093.
25. Darbousset R, Thomas GM, Mezouar S, Frère C, Bonier R, Mackman N, Renné T, Dignat-George F, Dubois C, Panicot-Dubois L. Tissue factor-positive neutrophils bind to injured endothelial wall and initiate thrombus formation. Blood 2012, 120:2133-2143. 10.1182/blood-2012-06-437772, 22837532.
26. Fuchs TA, Abed U, Goosmann C, Hurwitz R, Schulze I, Wahn V, Weinrauch Y, Brinkmann V, Zychlinsky A. Novel cell death program leads to neutrophil extracellular traps. J Cell Biol 2007, 176:231-241. 10.1083/jcb.200606027, 17210947.
27. Clark SR, Ma AC, Tavener SA, McDonald B, Goodarzi Z, Kelly MM, Patel KD, Chakrabarti S, McAvoy E, Sinclair GD, Keys EM, Allen-Vercoe E, Devinney R, Doig CJ, Green FH, Kubes P. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med 2007, 13:463-469. 10.1038/nm1565, 17384648.
28. von Brühl ML, Stark K, Steinhart A, Chandraratne S, Konrad I, Lorenz M, Khandoga A, Tirniceriu A, Coletti R, Köllnberger M, Byrne RA, Laitinen I, Walch A, Brill A, Pfeiler S, Manukyan D, Braun S, Lange P, Riegger J, Ware J, Eckart A, Haidari S, Rudelius M, Schulz C, Echtler K, Brinkmann V, Schwaiger M, Preissner KT, Wagner DD, Mackman N, Engelmann B, Massberg S. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012, 209:819-835. 10.1084/jem.20112322.
29. Fuchs TA, Bhandari AA, Wagner DD. Histones induce rapid and profound thrombocytopenia in mice. Blood 2011, 118:3708-3714. 10.1182/blood-2011-01-332676, 21700775.
30. Kambas K, Mitroulis I, Apostolidou E, Girod A, Chrysanthopoulou A, Pneumatikos I, Skendros P, Kourtzelis I, Koffa M, Kotsianidis I, Ritis K: Autophagy mediates the delivery of thrombogenic tissue factor to neutrophil extracellular traps in human sepsis. PLoS One 2012, 7:e45427.
31. Iba T, Miki T, Hashiguchi N, Tabe Y, Nagaoka I. Combination of antithrombin and recombinant thrombomodulin modulates neutrophil cell-death and decreases circulating DAMPs levels in endotoxemic rats. Thromb Res 2014, 134:169-173. 10.1016/j.thromres.2014.04.015, 24816370.
32. Iba T, Miki T, Hashiguchi N, Yamada A, Nagaoka I. Combination of antithrombin and recombinant thrombomodulin attenuates leukocyte-endothelial interaction and suppresses the increase of intrinsic damage-associated molecular patterns in endotoxemic rats. J Surg Res 2014, 187:581-586. 10.1016/j.jss.2013.10.058, 24296334.
33. Triantaphyllopoulos DC. Effects of human antithrombin III on mortality and blood coagulation induced in rabbits by endotoxin. Thromb Haemost 1984, 51:232-235. 6377565.
34. Taylor FB, Emerson TE, Jordan R, Chang AK, Blick KE. Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons. Circ Shock 1988, 26:227-235. 3061681.
35. Emerson TE, Fournel MA, Leach WJ, Redens TB. Protection against disseminated intravascular coagulation and death by antithrombin-III in the Escherichia coli endotoxemic rat. Circ Shock 1987, 21:1-13. 3545529.
36. Dickneite G, Paques EP. Reduction of mortality with antithrombin III in septicemic rats: a study of Klebsiella pneumoniae-induced sepsis. Thromb Haemost 1993, 69:98-102. 8456437.
37. Iba T, Yagi Y, Kidokoro A, Ohno Y, Tankaka H, Kaneshiro Y, Kaneko K. Protective effects of antithrombin III on organ dysfunction induced by the continuous infusion of endotoxin in rats. Jpn Assoc Acute Med 1998, 9:45-52.
38. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709. 10.1056/NEJM200103083441001, 11236773.
39. Hoffmann JN, Wiedermann CJ, Juers M, Ostermann H, Kienast J, Briegel J, Strauss R, Warren BL, Opal SM. Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thromb Haemost 2006, 95:850-856. 16676077.
40. Wiedermann CJ, Hoffmann JN, Juers M, Ostermann H, Kienast J, Briegel J, Strauss R, Keinecke HO, Warren BL, Opal SM. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med 2006, 34:285-292. 10.1097/01.CCM.0000194731.08896.99, 16424704.
41. Iba T, Saito D, Wada H, Asakura H. Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a prospective multicenter survey. Thromb Res 2012, 130:e129-e133. 10.1016/j.thromres.2012.03.021, 22542365.
42. Iba T, Saitoh D, Wada H, Asakura H: Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a secondary survey. Crit Care 2014, 18:497.
43. Nakahara K, Okuse C, Adachi S, Suetani K, Kitagawa S, Okano M, Michikawa Y, Takagi R, Shigefuku R, Itoh F. Use of antithrombin and thrombomodulin in the management of disseminated intravascular coagulation in patients with acute cholangitis. Gut Liver 2013, 7:363-370. 10.5009/gnl.2013.7.3.363, 23710320.
44. Tagami T, Matsui H, Horiguchi H, Fushimi K, Yasunaga H. Antithrombin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study. J Thromb Haemost 2014, 12:1470-1479. 24943516.
45. Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Marey A, Lestavel P. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992, 101:816-823. 10.1378/chest.101.3.816, 1531791.
46. Lauterbach R, Pawlik D, Radziszewska R, Wozniak J, Rytlewski K. Plasma antithrombin III and protein C levels in early recognition of late-onset sepsis in newborns. Eur J Pediatr 2006, 165:585-589. 10.1007/s00431-006-0139-7, 16636814.
47. Rodeghiero F, Mannucci PM, Viganò S, Barbui T, Gugliotta L, Cortellaro M, Dini E. Liver dysfunction rather than intravascular coagulation as the main cause of low protein C and antithrombin III in acute leukemia. Blood 1984, 63:965-969. 6584188.
48. Sié P, Letrenne E, Caranobe C, Genestal M, Cathala B, Boneu B. Factor II related antigen and antithrombin III levels as indicators of liver failure in consumption coagulopathy. Thromb Haemost 1982, 47:218-220. 6810490.
49. Jordan RE, Kilpatrick J, Nelson RM. Heparin promotes the inactivation of antithrombin by neutrophil elastase. Science 1987, 237:777-779. 10.1126/science.3649921, 3649921.
50. Seitz R, Wolf M, Egbring R, Havemann K. The disturbance of hemostasis in septic shock: role of neutrophil elastase and thrombin, effects of antithrombin III and plasma substitution. Eur J Haematol 1989, 43:22-28. 10.1111/j.1600-0609.1989.tb01246.x, 2788582.
51. Iba T, Yagi Y, Kidokoro A. The role of the endothelium in changes in procoagulant activity in sepsis. J Am Coll Surg 1998, 187:321-329. 10.1016/S1072-7515(98)00177-X, 9740191.
52. Pettila V, Pentti J, Pettila M, Takkunen O, Jousela I. Predictive value of antithrombin III and serum C-reactive protein concentration in critically ill patients with suspected sepsis. Crit Care Med 2002, 30:271-275. 10.1097/00003246-200202000-00001, 11889291.
53. Iba T, Kidokoro A, Fukunaga M, Sugiyama K, Kato H. Association between the severity of sepsis and the changes in hemostatic molecular markers and vascular endothelial damage markers. Shock 2005, 23:25-29. 10.1097/01.shk.0000144422.32647.b6, 15614127.
54. Choi Q, Hong KH, Kim JE, Kim HK. Changes in plasma levels of natural anticoagulants in disseminated intravascular coagulation: high prognostic value of antithrombin and protein C in patients with underlying sepsis or severe infection. Ann Lab Med 2014, 34:85-91. 10.3343/alm.2014.34.2.85, 24624342.
55. Cauchie P, Cauchie C, Boudjeltia KZ, Carlier E, Deschepper N, Govaerts D, Migaud-Fressart M, Woodhams B, Brohée D. Diagnosis and prognosis of overt disseminated intravascular coagulation in a general hospital-meaning of the ISTH score system, fibrin monomers, and lipoprotein-C-reactive protein complex formation. Am J Hematol 2006, 81:414-419. 10.1002/ajh.20597, 16680742.
56. Iba T, Gando S, Murata A, Kushimoto S, Saitoh D, Eguchi Y, Ohtomo Y, Okamoto K, Koseki K, Mayumi T, Ikeda T, Ishikura H, Ueyama M, Ogura H, Endo S, Shimazaki S. Predicting the severity of SIRS-associated coagulopathy with hemostatic molecular markers and vascular endothelial injury markers. J Trauma 2007, 63:1093-1098. 10.1097/01.ta.0000251420.41427.d3, 17993956.
57. Yanagida Y, Gando S, Sawamura A, Hayakawa M, Uegaki S, Kubota N, Homma T, Ono Y, Honma Y, Wada T, Jesmin S. Normal prothrombinase activity, increased systemic thrombin activity, and lower antithrombin levels in patients with disseminated intravascular coagulation at an early phase of trauma: comparison with acute coagulopathy of trauma-shock. Surgery 2013, 154:48-57. 10.1016/j.surg.2013.02.004, 23684364.
58. Oshiro A, Yanagida Y, Gando S, Henzan N, Takahashi I, Makise H: Hemostasis during the early stages of trauma: comparison with disseminated intravascular coagulation. Crit Care 2014, 18:R61.
59. Favaloro EJ. Laboratory testing in disseminated intravascular coagulation. Semin Thromb Hemost 2010, 36:458-467. 10.1055/s-0030-1254055, 20614398.
60. Taylor FB, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001, 86:1327-1330. 11816725.
61. Gando S, Iba T, Eguchi Y, Ohtomo Y, Okamoto K, Koseki K, Mayumi T, Murata A, Ikeda T, Ishikura H, Ueyama M, Ogura H, Kushimoto S, Saitoh D, Endo S, Shimazaki S. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med 2006, 34:625-631. 16521260.
62. Oh D, Jang MJ, Lee SJ, Chong SY, Kang MS, Wada H. Evaluation of modified non-overt DIC criteria on the prediction of poor outcome in patients with sepsis. Thromb Res 2010, 126:18-23. 10.1016/j.thromres.2009.12.008, 20079919.
63. Egi M, Morimatsu H, Wiedermann CJ, Tani M, Kanazawa T, Suzuki S, Matsusaki T, Shimizu K, Toda Y, Iwasaki T, Morita K. Non-overt disseminated intravascular coagulation scoring for critically ill patients: the impact of antithrombin levels. Thromb Haemost 2009, 101:696-705. 19350114.